The asthma drug montelukast (Singulair) will carry more prominent warnings in the UK to alert doctors and patients to its potentially serious behavioural and neuropsychiatric side effects.
Previously noted side effects associated with the oral treatment include sleep disturbances, depression, and agitation (which may affect up to one in 100 people); disturbances of attention or memory (up to one in 1000); and hallucinations and suicidal …